

1 **Diagnostic accuracy of the Point-of-Care Standard G6PD test™ (SD Biosensor) for**  
2 **Glucose-6-phosphate dehydrogenase deficiency: a systematic review of the literature**

3

4 **Short title: Diagnostic accuracy of a Point-of-Care Standard G6PD test**

5

6 Juan Camilo Martínez<sup>1\*</sup>, Viviana Vélez-Marín<sup>1</sup>, Mary Lopez-Perez<sup>2</sup>, Daniel Felipe Patiño<sup>1</sup>,  
7 Ivan D. Florez<sup>1,3,4,5\*</sup>

8

9 <sup>1</sup>Unit of evidence and deliberation for decision making UNED, Medical Research Institute,  
10 School of Medicine, University of Antioquia UdeA

11 <sup>2</sup>Centre for Medical Parasitology, Department for Immunology and Microbiology, Faculty  
12 of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

13 <sup>3</sup>Department of Pediatrics, School of Medicine, University of Antioquia UdeA, Av. St 70  
14 No. 52-21, Medellin, Colombia.

15 <sup>4</sup>School of Rehabilitation Science, McMaster University, Hamilton, Canada

16 <sup>5</sup>Pediatric Intensive Care Unit, Clinica Las Americas-AUNA, Medellin, Colombia

17 **\*Corresponding author:** E-mail: [ivan.florez@udea.edu.co](mailto:ivan.florez@udea.edu.co). School of medicine,  
18 University of Antioquia UdeA, Av. St 70 No. 52-21, Medellin, Colombia.

## 19 **Abstract**

20 Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic  
21 enzymopathy that can induce hemolysis triggered by various factors, including some anti-  
22 malarial drugs. Although many Point-of-Care (PoC) tests, such as STANDARD G6PD™  
23 manufactured by SD biosensor (StandG6PD-BS), are available to detect G6PDd, its pooled  
24 diagnostic test accuracy (DTA) remains unknown. To estimate the DTA of StandG6PD-BS  
25 at various thresholds of G6PDd, we conducted a systematic review with a DTA meta-  
26 analysis, searching EMBASE, MEDLINE, and SciELO databases up to June 30, 2023. We  
27 included studies measuring G6PD activity using StandG6PD-BS (reference test) and  
28 spectrophotometry (gold standard) in patients suspected of having G6PDd. We assessed the  
29 risk of bias (RoB) of the studies using the QUADAS-2 tool and the certainty of evidence  
30 (CoE) with the GRADE approach. Our approach included the estimation of within-study  
31 DTA, a random-effect bivariate meta-analysis to determine the pooled sensitivity and  
32 specificity for 30%, 70%, and 80% enzyme levels' thresholds, and a graphical analysis of  
33 the heterogeneity using crosshair and Confidence Regions on receiver operating  
34 characteristic (ROC) space plots. After screening 2,407 reports, we included four studies  
35 with 7,864 participants covering all thresholds. Two studies had high RoB in QUADAS-2  
36 domains 2 and 3, and the others had low RoB. We also found low, moderate, and high  
37 heterogeneity at the 30%, 70%, and 80% thresholds, respectively. The pooled sensitivity  
38 was 99.1% (95%CI 96.9-99.7%, CoE: high), 95.7% (92.0-97.0%, high), and 90% (78.0-  
39 96.5%, low) for 30%, 70%, and 80% thresholds, respectively. The pooled specificity was  
40 97.4% (95%CI 95.0; 98.4%, high); 92.9% (85.0-96.4%, high); and 89.0% (76.0-96.0%,

41 moderate) for 30%, 70%, and 80% thresholds, respectively. In conclusion, StandG6PD-BS  
42 is a PoC test with high sensitivity and specificity to detect G6PDd at different thresholds.

### 43 **Author summary**

44 Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic disease that  
45 can induce the destruction of red blood cells leading to anemia triggered by various factors,  
46 including some drugs used for malaria treatment. After a literature search in different  
47 databases up to January 31, 2023, we pooled diagnostic test accuracy of the Point-of-Care  
48 (PoC) STANDARD G6PDTM test manufactured by SD biosensor (StandG6PD-BS) used  
49 to identify the G6PDd. Although two of the four studies included showed a high Risk of  
50 Bias related to the index test and the reference standard domains of the QUADAS-2 tool,  
51 the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels' thresholds  
52 were around 90%, with better sensitivity and specificity values for the 30% threshold  
53 (99.1% and 97.4%) compared with 70% (95.7% and 92.9%) and 80% (90% and 89%)  
54 threshold. We found low, moderate, and high heterogeneity at the 30%, 70%, and 80%  
55 thresholds. In conclusion, StandG6PD-BS is a PoC test with high sensitivity and specificity  
56 to detect G6PDd at different thresholds.

57 **Keywords:** systematic review, metanalysis, Glucose-6-phosphate dehydrogenase, malaria,  
58 Point-of-Care test, STANDARD G6PD™.

## 59 Introduction

60 Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is a genetic disorder linked to the  
61 X chromosome, with hemizygous males and homozygous females having a deficient  
62 activity phenotype (< 30% of enzyme levels). In contrast, heterozygous females may have a  
63 normal (> 80%) or intermediate activity phenotype (30% to 80% enzyme level) (1).  
64 Individuals with deficient activity may experience hemolytic episodes triggered by intrinsic  
65 or extrinsic factors such as medications or certain foods (2). G6PDd is the most common  
66 enzymopathy in humans, with variable frequencies and distinctive region-specific  
67 distribution (3). It is particularly common in malaria-endemic regions (1,4), with an  
68 estimated frequency of 8%- 10% (~350 to 400 million cases per year) and over 200  
69 identified genetic polymorphisms (5). This overlapping is attributed to the protective effect  
70 of G6PDd against malaria (1).

71 Malaria caused by *Plasmodium vivax* is geographically widespread and counts for most  
72 cases outside Africa, particularly in the Americas and South-East Asia (6). Primaquine  
73 (PQ) and the novel tafenoquine (TQ) are the only two approved drugs for treating hepatic  
74 stages and are used for the radical cure of uncomplicated malaria by *P. vivax* (5,7).  
75 However, these drugs may precipitate hemolytic crises in individuals with G6PDd (1,5,7),  
76 with the severity of the reaction being proportional to the dose of the medication received  
77 and the enzyme genotype (5,7). To ensure safe administration of these drugs, the World  
78 Health Organization (WHO) recommends testing for G6PDd in those requiring treatment  
79 with PQ (7). This could be achieved by using Point-of-Care (PoC) tests to determine G6PD

80 activity before administering PQ and TQ, as has been recommended by multiple studies  
81 (8).

82 Several tests are currently available to determine the G6PD activity, but they have different  
83 performance (9,10). Since the gold standard for G6PD measurement (spectrophotometry) is  
84 not suitable for PoC testing, qualitative tests have been developed with variable diagnostic  
85 performance and operational characteristics (11–13). While those tests discriminate  
86 between normal and deficient G6PD activity and therefore are sufficient to guide PQ  
87 treatment, they may not be dependable enough to prevent drug-induced hemolysis with the  
88 introduction of TQ. Consequently, more reliable diagnostic tests are required, and one of  
89 such test is the semi-quantitative assay STANDARD G6PD™ (SD biosensor, Republic of  
90 Korea), an enzymatic colorimetric assay intended to aid the detection of G6PDd (14). This  
91 PoC test provides a numeric measurement of G6PD enzymatic activity and total  
92 hemoglobin (Hb) concentration in fresh capillary and venous human whole blood  
93 specimens (14) and allows classification of the G6PD activity as deficient, intermediate, or  
94 normal according to thresholds provided by the manufacturer (14).

95 Despite the recommendation for PoC quantitative or semi-quantitative testing before  
96 administering antimalarial treatment, there is only one synthesis of the diagnostic test  
97 accuracy (DTA) of the STANDARD G6PD™ test manufactured by SD Biosensor  
98 (StandG6PD-BS) (15) in which the authors pooled the individual results of various studies  
99 without a complete systematic review approach, risk of bias, and certainty of evidence  
100 assessment. In this systematic review and metaanalysis, we estimated the pooled DTA of the  
101 StandG6PD-BS for different thresholds of G6PD activity.

102

## 103 **Materials and methods**

### 104 **Protocol and registration**

105 This systematic review and DTA meta-analysis were conducted and reported following the  
106 Preferred Reporting Items for Systematic Reviews and Meta-analyses of DTA Studies  
107 (PRISMA-DTA) guidelines. The protocol was registered in the PROSPERO database  
108 (CRD42022311085).

### 109 **Search and study selection**

110 Two authors (JCM, VVM) performed a structured search in MEDLINE (via PubMed),  
111 EMBASE, and SciELO databases on August 2<sup>nd</sup>, 2022, and updated it on January 31, 2023,  
112 and on June 30, 2023 without language or date restrictions. Our search strategy is outlined  
113 in **Table S1**. We included prospective or retrospective studies that measured G6PD activity  
114 levels using the reference standard enzymatic test (spectrophotometry G6PD assay) and the  
115 reference test (StandG6PD-BS). The studies must have reported enough data to calculate  
116 diagnostic performance measures, i.e., true positives (TP), true negatives (TN), false  
117 positives (FP), and false negatives (FN), for at least one threshold (30%, 70%, and 80%) of  
118 G6PD activity.

119 Using Rayyan software (Rayyan QCRI, Qatar) (16), two authors screened titles and  
120 abstracts retrieved from searches, and only those records considered eligible by both  
121 reviewers were retrieved in full texts for the next stage. The same authors (JCM, VVM)  
122 reviewed the potentially eligible full texts, independently and in duplicate, based on the  
123 pre-specified inclusion criteria. Those studies considered eligible by both reviewers were

124 included. Disagreements were resolved by consensus among the reviewers and with the  
125 participation of a third reviewer if needed (MLP, IDF).

126 The same authors (JCM, VVM) independently and in duplicate extracted the data from the  
127 included studies using a prespecified data extraction form designed in Google Forms  
128 (Google LLC, US), which was discussed and piloted among the research team. For each  
129 study, we extracted the following information: first author, year of publication, title,  
130 population, data for every threshold recommended by the manufacturer (SD biosensor®),  
131 number of participants, age (mean and standard deviation), sex, type of blood sample  
132 (venous or capillary), and the data needed for 2x2 contingency tables (TP, FP, FN, and  
133 TN). Disagreements in the data extraction process were discussed between the reviewers.

#### 134 **Risk of bias assessment and certainty of the evidence**

135 Two authors (JCM, VVM) independently assessed the Risk of Bias (RoB) for the included  
136 studies using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool  
137 (17). The QUADAS-2 instrument evaluates the RoB of DTA studies with four domains  
138 (patient selection, index test, reference standard, and flow and timing), judging each as  
139 high, low, or unclear in risk of bias and concerns regarding applicability. The authors  
140 discussed any disagreements and resolved them through consensus.

141 We assessed the Certainty of Evidence (CoE) using the GRADE framework for DTA  
142 systematic reviews (18,19). This approach evaluates four criteria: RoB (judged using the  
143 QUADAS-2 assessment), indirectness, inconsistency, publication bias and impression, and  
144 rates the certainty of the evidence in high, moderate, low, and very low.

## 145 **Statistical analysis**

146 We used R Software and the package *mada* (version 4.1.2, The R Foundation for Statistical  
147 Computing) for the statistical analyses (20) and the GRADE Pro GDT platform (McMaster  
148 University 2015, developed by EvidencePrime, Inc) for creating the Summary of Findings  
149 (SoF) tables. First, we calculated sensitivity, specificity, positive likelihood ratio (+LR),  
150 negative likelihood ratio (-LR), and diagnostic odds ratio (DOR) at every threshold. The  
151 cut-off recommended for the StandG6PD-BS test manufacturer is a valuable tool for  
152 therapeutic decisions because enzyme levels define the use of specific treatment. Thus,  
153 enzymatic levels above 30% allow using PQ and other drugs at specific doses; levels above  
154 70% allow using TQ and any PQ treatment schedule; and levels above 80% define a normal  
155 G6PD activity. Then, we fitted the type of blood sample data at each threshold with the  
156 *Reistma* model (21), a bivariate random-effect meta-analysis. With this approach, we  
157 calculated the pooled sensitivity, specificity, +LR, and -LR and their corresponding 95%  
158 confidence intervals (95% CI) utilizing model estimations. We used data only from female  
159 participants at 70% and 80% thresholds. We pooled the results for venous blood samples  
160 because the combined capillary samples were too small and not measured in all the studies.

161 For between-studies heterogeneity, we used visual inspection of forest plots for DTA  
162 pooled measures, crosshair plots (sensitivity vs. false positive rate), confidence regions in  
163 the *Receiver Operating Characteristic* (ROC) space, evaluating the overlap in the  
164 confidence intervals, and *chi-square* test for homogeneity ( $p$ -values  $<0.05$  were considered  
165 significant, and therefore as with heterogeneity). We did not obtain enough studies to fit the  
166 sensitivity analysis models as stated in the registered protocol.



## 167 **Results**

### 168 **Search results**

169 We obtained 2,818 records and after removing duplicates, we screened 2,407 unique  
170 reports and identified nine potentially eligible studies. After the full-text assessment, we  
171 excluded five and included four studies that met the inclusion criteria for qualitative and  
172 quantitative synthesis (**Figure 1**).

173 **Figure 1.** PRISMA flow diagram indicating the process of inclusion and exclusion of  
174 studies.

### 175 **Included and excluded studies**

176 We excluded five studies (**Table S2**) because of the different populations, reference tests,  
177 or outcomes (i.e., neither provides DTA measures nor data to calculate them; **Table S2**).

178 **Table 1** summarizes the characteristics of the four included studies (22–25). These studies  
179 were conducted in the United States (U.S.) (22,25), United Kingdom (U.K.) (22), Brazil  
180 (23), Bangladesh (24), and Thailand (25). In total, they included 3,122 (30% thresholds of  
181 the StandG6PD-BS), 2,371 (70%), and 2,371 (80%) participants for each test analysis,  
182 respectively. All studies were cross-sectional DTA, two included healthy adults ( $\geq 18$  years  
183 old) (22,25), one included participants older than two years (23), and three studies included  
184 individuals with known G6PD status (23–25). The reference test used in all the studies was  
185 spectrophotometry for the G6PD kit (Pointe Scientific).

186 **Table 1.** Characteristics of included studies

187

188 **Risk of Bias (RoB)**

189 Two studies were judged as high (24,25), and two as low RoB in domain one (22,23)  
190 (patient selection) of the QUADAS-2 tool. One study was judged high (24), two unclear  
191 (22,25), and one low RoB in domain four (23) (flow and timing). All studies had low RoB  
192 and applicability concerns in domains two and three (reference test and standard). This  
193 information is presented as a table and diagram using the QUADAS-2 tool resources  
194 **(Figure 2)**.

195

196 **Figure 2.** RoB summary judgements about each included study using QUADAS-2 tool.

197

198 **Diagnostic test accuracy from primary studies and pooled data**

199 Sensitivities and specificities from primary studies are presented in **Figure 3**. Sensitivity  
200 ranged from 91% to 99%, whereas specificities were from 89% to 97% for 30% and 80%  
201 thresholds, respectively. **Figure 3** displays the crosshair plot (sensitivity vs. false positive  
202 rates) for the three thresholds. Positive and negative LR from studies are presented in  
203 **Figure S1**. Pooled DTA measures for each G6PD activity threshold are described (**Table**  
204 **2**). Pooled results showed high DTA measures for all the thresholds being better for lower  
205 than the highest threshold. Positive and negative LR ranged from 8.2 to 35.3 and 0.009 to  
206 0.106. The CoE for sensitivity and specificity was high for 30% and 70% thresholds, but  
207 for 80% threshold sensitivity was low and specificity was moderate due to concerns in the  
208 RoB, indirectness, inconsistency, and imprecision (See **Table S3**).

209 We found low, moderate, and high heterogeneity in the results for the 30%, 70%, and 80%  
210 thresholds, respectively (**Figure 4 and 5**).

211

212 **Table 2.** Pooled DTA values for each threshold defined by Standard™ G6PD (SD  
213 Biosensor) test.

214

215 **Figure 3.** Pooled Sensitivity and Specificity for Standard™ G6PD (SD Biosensor) in  
216 venous blood samples.

217

218

219 **Figure 4.** Crosshair plot for each threshold defined by the Standard™ G6PD (SD  
220 Biosensor) test.

221

222 **Figure 5.** SROC curve (bivariate model) for different Standard G6PD (SD Biosensor)  
223 thresholds in venous blood samples.

## 224 **Discussion**

225 In this systematic review, we included four studies evaluating 7,864 patients and found that  
226 StandG6PD-BS is a semi-quantitative PoC test with high sensitivity and specificity values  
227 to detect G6PDd at the different G6PD activity thresholds recommended by the  
228 manufacturer (30%, 70%, and 80%). The test showed better performance and CoE for 30%  
229 and 70%, compared with the 80% threshold. Likewise, the heterogeneity in the results was  
230 low, moderate, and high at 30%, 70%, and 80% thresholds, respectively.

231 The included studies were conducted in both high and low-middle-income countries, and  
232 participants were predominantly healthy adults with or without known G6PD status. This  
233 allows the decision-makers to assess the potential impact of implementing the StandG6PD-  
234 BS PoC test in the general population, particularly for uncomplicated malaria by *P. vivax*.  
235 The evidence suggests that introducing this test in tropical and subtropical malaria-endemic  
236 countries with *P. vivax* high transmission regions would be both feasible and desirable and  
237 could provide numerous benefits (5,7,26). For instance, a recent study in Brazil (26) found  
238 that combining TQ treatment with the StandG6PD-BS test improved the response to radical  
239 cure treatment by enhancing adherence, reducing relapses, and increasing protection against  
240 new *P. vivax* infections.

241 The literature describes factors related to lower test accuracy that may not be explained just  
242 by the PoC test performance. A recent controlled study suggested that the StandG6PD-BS  
243 test performed well in venous blood, exhibiting good repeatability and inter-laboratory  
244 reproducibility (27). However, the same study found that the reliability of the test was poor  
245 in discriminating between intermediate and low G6PD activities in lyophilized samples

246 (27), emphasizing the need for further research in field-based scenarios. This study found  
247 similar estimates for sensitivity and specificity as reported by Addisu et al. (15). However,  
248 our work is the first to conduct a complete systematic review approach through a  
249 comprehensive search and selection, a random model meta-analysis, risk of bias  
250 assessment, and certainty of evidence using the GRADE approach and following the  
251 methods recommended by the Cochrane collaboration.

252 In our approach, we pooled only results of venous blood samples because other sources,  
253 such as capillary and lyophilized blood, provided limited results due to small sample sizes  
254 in the studies and differences in the specimen collection and lyophilization methods.  
255 Nevertheless, some evidence suggests that capillary and lyophilized blood samples could  
256 drive less accuracy in the PoC test results (22,27–29).

257 In the included studies, only one (25) used frozen venous blood to run the StandG6PD-BS  
258 test showing slightly less DTA than the fresh venous blood samples (25). This could be due  
259 to the small number of participants, the specimen collection, or the storage method. An  
260 alternative cause is the study population (Thailand), which carries the G6PDd Mahidol  
261 phenotype with moderate enzymatic activity (30-70%). However, the StandG6PD-BS  
262 sensibilities and specificities at those levels are still around 90% (22,27,30).

263 The current evidence strongly supports the implementation of the PoC test for G6PD  
264 activity. At the individual level, it will enable the safe treatment of more patients with  
265 deficient and intermediate G6PD activity, diminishing the risk of recurrent malaria and  
266 acute hemolytic anemia (5,7,31,32). At the healthcare systems level, it could reduce the  
267 associated costs and the burden on transfusion services by reducing the number of

268 hemolytic crises caused by PQ or TQ in individuals with unknown G6PD status and  
269 malaria treatment (5,7,31,33). Additionally, this could impact parasite transmission rates  
270 when combined with other interventions (5,7,31). Given that up to 50% of the patients with  
271 *P. vivax* malaria may experience relapses (5,7), administering radical cure with PQ or TQ is  
272 essential for stopping morbidity-related and community transmission (5,7,26,32).

273 Our work has several strengths. This systematic review with meta-analysis is the first to  
274 evaluate the DTA of the StandG6PD-BS test. Moreover, we followed state-of-the-art  
275 methodologies for conducting DTA studies, as recommended by the Cochrane Handbook  
276 for Systematic Reviews of Diagnostic Test Accuracy (34). We prepared the final report of  
277 this review following the recommendations by the PRISMA-DTA statement (35). We also  
278 provided information on the pooled sensitivity and specificity for each threshold, which can  
279 facilitate decision-making in different clinical scenarios.

280 We also recognize some limitations. First, the number of studies was low, preventing us  
281 from performing additional analyses, such as sensibility analysis. Additionally, the quality  
282 of some studies was not optimal, although our analysis is robust enough to show adequate  
283 pooled DTA measures for venous blood samples. Future studies using capillary and  
284 lyophilized blood, along with field-based studies, are needed to determine the appropriate  
285 usage of this test. A study on barriers and facilitators for G6PD test implementation (36)  
286 identified three main barriers: perceived low risk of hemolysis, wrong perception of *P.*  
287 *vivax* malaria as a benign condition, and the cost of routine testing as part of the healthcare  
288 attention of malaria patients. A study conducted in Brazil on the operational challenges  
289 associated with pragmatic G6PD testing (37) found that the StandG6PD-BS PoC test was  
290 well accepted by both healthcare professionals and patients and can be performed at

291 malaria treatment units in the Brazilian Amazon to inform treatment decisions with PQ.  
292 However, the authors found limitations linked to technical and cultural aspects that should  
293 be addressed when expanding screening to larger areas (37).

## 294 **Conclusion**

295 StandG6PD-BS is a PoC test with high sensitivity and specificity to detect G6PDd at the  
296 different thresholds recommended by the manufacturer (30%, 70%, and 80%).  
297 Implementing this kind of test in malaria-endemic areas can lead to early diagnosis of  
298 G6PDd, help to prevent hemolytic episodes triggered by PQ or TQ, and potentially impact  
299 malaria transmission.

## 300 **Acknowledgments**

301 We acknowledge Dr Lina Gaviria (Haematologist, Universidad de Antioquia, Colombia),  
302 for their contribution to the conceptualization of this study; Marina Figueira, and Camilo  
303 Manchola (Global Health Strategies), Jonathan Novoa (Medicines for Malaria Venture),  
304 and Jamil Barton and Reina Jara (Program for Appropriate Technology in Health) for their  
305 contribution in this study.

306

## 307 **Data Availability Statement**

308 The data are available on request from the authors.

## 309 **Funding**

310 This work and its authors (JCM, VVM, MLP, DPL, IDF) were supported, in whole part, by  
311 the Bill & Melinda Gates Foundation through a sub-agreement with Global Health  
312 Strategies (GHS) as part of the project: "**Cost-effectiveness of Tafenoquine in the radical**  
313 **cure of *Plasmodium vivax* malaria**" (Grant Number OPP1194815). Under the grant  
314 conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has  
315 already been assigned to the Author Accepted Manuscript version that might arise from this  
316 submission (<https://globalhealthstrategies.com>). MLP is supported by Independent  
317 Research Fund Denmark (grant 013400123B; <https://dff.dk/en>). The funders had no role in  
318 study design, data collection and analysis, decision to publish, or preparation of the  
319 manuscript.



320 **Competing interest**

321 The authors declare no competing interests.

322 **Author's contributions**

323 **Conceptualization:** JCM, IDF.

324 **Data curation:** JCM, VVM.

325 **Formal analysis:** JCM, VVM, IDF, MLP

326 **Funding acquisition:** IDF, DFP.

327 **Investigation:** IDF, DFP, JCM, VVM.

328 **Methodology:** JCM, VVM.

329 **Project administration:** JCM.

330 **Resources:** IDF.

331 **Software:** JCM

332 **Supervision:** IDF, DFP.

333 **Visualization:** JCM, VVM.

334 **Writing – original draft:** VVM, JCM.

335 **Writing – review & editing:** JCM, VVM, DFP, IDF, MLP.

336 ORCID IDs:

337 JCM: <https://orcid.org/0000-0001-6420-7797>

338 VVM: <https://orcid.org/0000-0002-9430-3912>

339 MLP <https://orcid.org/0000-0002-9876-0248>

340 DFP: <https://orcid.org/0000-0003-4030-4255>

341 IDF: <https://orcid.org/0000-0002-0751-8932>

342

## 343 **References**

- 344 1. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. Chapter Four - G6PD  
345 Deficiency: Global Distribution, Genetic Variants and Primaquine Therapy. In: Hay  
346 SI, Price R, Baird JKBT-A in P, editors. *The Epidemiology of Plasmodium vivax*  
347 [Internet]. Academic Press; 2013. p. 133–201. Available from:  
348 <https://www.sciencedirect.com/science/article/pii/B9780124078260000047>
- 349 2. Bancone G, Chu CS. G6PD Variants and Haemolytic Sensitivity to Primaquine and  
350 Other Drugs. *Front Pharmacol*. 2021;12:638885.
- 351 3. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence  
352 of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-  
353 analysis. *Blood Cells, Mol Dis* [Internet]. 2009;42(3):267–78. Available from:  
354 <https://www.sciencedirect.com/science/article/pii/S1079979609000059>
- 355 4. Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, et al. Spatial  
356 distribution of G6PD deficiency variants across malaria-endemic regions. *Malar J*  
357 [Internet]. 2013;12(1):418. Available from: [https://doi.org/10.1186/1475-2875-12-](https://doi.org/10.1186/1475-2875-12-418)  
358 418
- 359 5. Chu CS, White NJ. The prevention and treatment of Plasmodium vivax malaria.  
360 *PLoS Med*. 2021;18(4 April):1–21.
- 361 6. World Health Organization (WHO). *World Malaria Report 2023*. 2023.
- 362 7. Organización Mundial de la Salud OMS. Testing for G6PD deficiency for safe use of  
363 primaquine in radical cure of P. vivax and P. ovale malaria Policy brief. Geneva;  
364 2016.

- 365 8. Malaria Policy Advisory Committee Meeting. Point-of-care G6PD testing to support  
366 safe use of primaquine for the treatment of vivax malaria. Geneva; 2015.
- 367 9. LaRue N, Kahn M, Murray M, Leader BT, Bansil P, McGray S, et al. Comparison of  
368 Quantitative and Qualitative Tests for Glucose-6-Phosphate Dehydrogenase  
369 Deficiency. *Am Soc Trop Med Hyg* [Internet]. 2014;91(4):854–61. Available from:  
370 <https://www.ajtmh.org/view/journals/tpmd/91/4/article-p854.xml>
- 371 10. Espino FE, Bibit J-A, Sornillo JB, Tan A, von Seidlein L, Ley B. Comparison of  
372 Three Screening Test Kits for G6PD Enzyme Deficiency: Implications for Its Use in  
373 the Radical Cure of Vivax Malaria in Remote and Resource-Poor Areas in the  
374 Philippines. *PLoS One* [Internet]. 2016;11(2):1–12. Available from:  
375 <https://doi.org/10.1371/journal.pone.0148172>
- 376 11. Osorio L, Carter N, Arthur P, Bancone G, Gopalan S, Gupta SK, et al. Performance  
377 of BinaxNOW G6PD Deficiency Point-of-Care Diagnostic in *P. vivax*-Infected  
378 Subjects. *Am Soc Trop Med Hyg* [Internet]. 2015;92(1):22–7. Available from:  
379 <https://www.ajtmh.org/view/journals/tpmd/92/1/article-p22.xml>
- 380 12. Ley B, Bancone G, von Seidlein L, Thriemer K, Richards JS, Domingo GJ, et al.  
381 Methods for the field evaluation of quantitative G6PD diagnostics: a review. *Malar J*  
382 [Internet]. 2017;16(1):361. Available from: [https://doi.org/10.1186/s12936-017-](https://doi.org/10.1186/s12936-017-2017-3)  
383 [2017-3](https://doi.org/10.1186/s12936-017-2017-3)
- 384 13. Brito MAM, Peixoto HM, de Almeida ACG, de Oliveira MRF, Romero GAS,  
385 Moura-Neto JP, et al. Validation of the rapid test Carestart(tm) G6PD among malaria  
386 vivax-infected subjects in the Brazilian Amazon. *Rev Soc Bras Med Trop* [Internet].  
387 2016 Jul 1 [cited 2022 Oct 21];49(4):446–55. Available from:

- 388 <http://www.scielo.br/j/rsbmt/a/5pRMqmmgJbk7LvHNBwPXCVD/?lang=en>
- 389 14. PATH. G6PD Operational Research Community of Practice. 2022.
- 390 15. Adissu W, Brito M, Garbin E, Macedo M, Monteiro W, Mukherjee SK, et al.
- 391 Clinical performance validation of the STANDARD G6PD test: A multi-country
- 392 pooled analysis. *PLoS Negl Trop Dis* [Internet]. 2023 Oct 12;17(10):e0011652.
- 393 Available from: <https://doi.org/10.1371/journal.pntd.0011652>
- 394 16. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan---a web and
- 395 mobile app for systematic reviews. *Syst Rev* [Internet]. 2016;5(1):210. Available
- 396 from: <http://dx.doi.org/10.1186/s13643-016-0384-4>
- 397 17. Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J, et al. QUADAS-
- 398 2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. *Ann*
- 399 *Intern Med* [Internet]. 2011;155(8):529–36. Available from:
- 400 <https://www.acpjournals.org/doi/abs/10.7326/0003-4819-155-8-201110180-00009>
- 401 18. Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeftang M, Murad MH, et
- 402 al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in
- 403 rating the certainty across a body of evidence for test accuracy. *J Clin Epidemiol*
- 404 [Internet]. 2020 Jun 1;122:129–41. Available from:
- 405 <https://doi.org/10.1016/j.jclinepi.2019.12.020>
- 406 19. Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeftang M, Murad MH, et
- 407 al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision,
- 408 publication bias, and other domains for rating the certainty of evidence and
- 409 presenting it in evidence profiles and summary of findings tables. *J Clin Epidemiol*


- 410 [Internet]. 2020 Jun 1;122:142–52. Available from:  
411 <https://doi.org/10.1016/j.jclinepi.2019.12.021>
- 412 20. Doebler P. mada: Meta-Analysis of Diagnostic Accuracy [Internet]. 2020. Available  
413 from: <https://cran.r-project.org/package=mada>
- 414 21. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH.  
415 Bivariate analysis of sensitivity and specificity produces informative summary  
416 measures in diagnostic reviews. *J Clin Epidemiol* [Internet]. 2005 Oct 1;58(10):982–  
417 90. Available from: <https://doi.org/10.1016/j.jclinepi.2005.02.022>
- 418 22. Pal S, Myburgh J, Bansil P, Hann A, Robertson L, Gerth-Guyette E, et al. Reference  
419 and point-of-care testing for G6PD deficiency: Blood disorder interference,  
420 contrived specimens, and fingerstick equivalence and precision. *PLoS One*.  
421 2021;16(9 September):1–24.
- 422 23. Zobrist S, Brito M, Garbin E, Monteiro WM, Clementino Freitas S, Macedo M, et al.  
423 Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate  
424 dehydrogenase deficiency in Brazil. *PLoS Negl Trop Dis* [Internet]. 2021;15(8):1–  
425 21. Available from: <https://doi.org/10.1371/journal.pntd.0009649>
- 426 24. Alam MS, Kibria MG, Jahan N, Thriemer K, Hossain MS, Douglas NM, et al. Field  
427 evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate  
428 dehydrogenase activity. *PLoS One* [Internet]. 2018;13(11):1–13. Available from:  
429 <https://doi.org/10.1371/journal.pone.0206331>
- 430 25. Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of  
431 a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency:

- 432 Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency  
433 Closer to the Patient. *Am J Trop Med Hyg* [Internet]. 2018;100(1):213–21.  
434 Available from: <https://www.ajtmh.org/view/journals/tpmd/100/1/article-p213.xml>
- 435 26. Nekkab N, Lana R, Lacerda M, Obadia T, Siqueira A, Monteiro W, et al. Estimated  
436 impact of tafenoquine for *Plasmodium vivax* control and elimination in Brazil: A  
437 modelling study. *PLoS Med*. 2021;18(4):1–19.
- 438 27. Ley B, Satyagraha AW, Kibria MG, Armstrong J, Bancone G, Bei AK, et al.  
439 Repeatability and reproducibility of a handheld quantitative G6PD diagnostic. *PLoS*  
440 *Negl Trop Dis*. 2022;16(2):1–17.
- 441 28. Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al.  
442 Evaluating Diagnostic Point-of-Care Tests in Resource-Limited Settings. *Lancet*  
443 *Infect Dis*. 2014 Mar;14(3):239–49.
- 444 29. Jameel F, Alexeenko A, Bhambhani A, Sacha G, Zhu T, Tchessalov S, et al.  
445 Recommended Best Practices for Lyophilization Validation 2021 Part II: Process  
446 Qualification and Continued Process Verification. *AAPS PharmSciTech*.  
447 2021;22(8).
- 448 30. Aung TH, Suansomjit C, Tun ZM, Hlaing TM, Kaewkungwal J, Cui L, et al.  
449 Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test  
450 among a population at risk of malaria in Myanmar. *Malar J*. 2023;22(1):143.
- 451 31. Garcia LS. Malaria. *Clin Lab Med*. 2010;30(1):93–129.
- 452 32. Llanos-Cuentas A, Manrique P, Rosas-Aguirre A, Herrera S, Hsiang MS.  
453 Tafenoquine for the treatment of *Plasmodium vivax* malaria. *Expert Opin*

- 454 Pharmacother. 2022;23(7):759–68.
- 455 33. Peixoto HM, Brito MAM, Romero GAS, Monteiro WM, de Lacerda MVG, de  
456 Oliveira MRF. Rapid diagnostic test for G6PD deficiency in Plasmodium vivax-  
457 infected men: a budget impact analysis based in Brazilian Amazon. Trop Med & Int  
458 Heal [Internet]. 2017;22(1):21–31. Available from:  
459 <https://onlinelibrary.wiley.com/doi/abs/10.1111/tmi.12800>
- 460 34. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy |  
461 Cochrane Training [Internet]. [cited 2022 Aug 14]. Available from:  
462 <https://training.cochrane.org/handbook-diagnostic-test-accuracy>
- 463 35. McInnes MDF, Moher D, Thoms BD, McGrath TA, Bossuyt PM, Group and the  
464 P-D. Preferred Reporting Items for a Systematic Review and Meta-analysis of  
465 Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA [Internet].  
466 2018 Jan 23;319(4):388–96. Available from:  
467 <https://doi.org/10.1001/jama.2017.19163>
- 468 36. Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Barriers to routine  
469 G6PD testing prior to treatment with primaquine. Malar J. 2017;16(1):1–10.
- 470 37. Brito-Sousa JD, Murta F, Vitor-Silva S, Sampaio V, Mendes M, Souza B, et al.  
471 Quantitative G6PD Deficiency Screening in Routine Malaria Diagnostic Units in the  
472 Brazilian Amazon (SAFEPRIM): An Operational Mixed-Methods Study. Pathogens.  
473 2022;11(11).
- 474




**Figure 1. PRISMA flow diagram indicating the process of inclusion and exclusion of studies.**



**Figure 2. Risk of Bias summary judgements about each included study using QUADAS-2 tool. QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies version**

2




**Figure 3. Pooled Sensitivity and Specificity for Standard™ G6PD (SD Biosensor) in venous blood samples.** Forest Plot for displaying the sensitivity and specificity per study according to specific thresholds with their corresponding 95% CI

### 30% Threshold

#### Sensitivities

#### Specificities

medRxiv preprint doi: <https://doi.org/10.1101/2024.02.10.24302326>; this version posted February 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



### 70% Threshold

#### Sensitivities

#### Specificities



### 80% Threshold


#### Sensitivities

#### Specificities






**Figure 4. Crosshair plot for each threshold defined by the Standard™ G6PD (SD Biosensor) test. DTA combined compared thresholds for Standard™ G6PD (SD Biosensor) in venous blood samples The crosshair plot colors correspond to thresholds: blue to 30%, green to 70%, and red to 80%.**

medRxiv preprint doi: <https://doi.org/10.1101/2024.02.10.24302326>; this version posted February 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



**Figure 5. SROC curve (bivariate model) for different thresholds for Standard™ G6PD (SD Biosensor) in venous blood samples.** Summary receiver operating characteristic (SROC) curve summarizing sensitivity and false positive rates according to the three thresholds, with the corresponding 95% confidence contour.

medRxiv preprint doi: <https://doi.org/10.1101/2024.02.10.24302326>; this version posted February 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



**Table 1.** Characteristics of included studies

| First Author | Year                | Study type          | Countries  | Study context   | Inclusion criteria  | Sample type        | Threshold | N for test operative characteristics (2x2 tables) |    |    |      |       | Reference (Index) test        | Gold Standard  | Observation   | Funding   |
|--------------|---------------------|---------------------|--|---|---|--------------------|-----------|---|----|----|------|-------|-------------------------------|--|---|---|
|              |                     |                     |  |   |   |                    |           | TP  | FN | FP | TN   | Total |                               |  |   |   |
| Pal (21)     | 2021                | Cross-sectional DTA | U.S. (three clinical centers) U.K.   | Healthy volunteers blood donors in different clinical centers                       | Healthy adults, ≥ 18 years old. They signed written informed consent.                         | Venous             | 30%       | 56  | 0  | 26 | 708  | 790   | STANDARD™ G6PD (SD Biosensor) | Spectrophotometry for G6PD using the kit Pointe Scientific   | None  | UK's FCDO, Bill & Melinda Gates fdn.                                    |
|              |                     |                     |  |   |   |                    | 70%       | 82  | 1  | 49 | 658  | 790   |                               |  |   |   |
|              |                     |                     |  |   |   |                    | 80%       | 85  | 16 | 58 | 631  | 790   |                               |  |   |   |
| Zobrist (22) | 2021                | Cross-sectional DTA | Brazil   | Febrile patients seeking care at the Manaus (924) and Porto Velho clinics (812)     | Participants ≥ 2 years old plus 69 belonged through an enriched sample for G6PD known status. | Venous             | 30%       | 56  | 0  | 23 | 1583 | 1662  | STANDARD™ G6PD (SD Biosensor) | Spectrophotometry for G6PD using the kit Pointe Scientific   | Measurement of temperature and humidity data at the time of testing that can affect PoC enzymatic activity test | UK's FCDO, Bill & Melinda Gates fdn., the National Institutes of Health |
|              |                     |                     |  |   |   |                    | 70%       | 31  | 1  | 31 | 848  | 911   |                               |  |   |   |
|              |                     |                     |  |   |   |                    | 80%       | 41  | 20 | 21 | 829  | 911   |                               |  |   |   |
| Alam (23)    | 2018                | Cross-sectional DTA | Bangladesh   | Participants were recruited in the Chittagong Hill Tracts districts (south-eastern) | Convenience sample from a cohort of adult with known G6PD status.                             | Venous             | 30%       | 30  | 0  | 0  | 76   | 106   | STANDARD™ G6PD (SD Biosensor) | Spectrophotometry for G6PD using the kit Pointe Scientific   | Review of test results changes in blood samples stored at room temperature (24 to 26°C) and 4°C.                | Wellcome Trust, Australian DFAT, Bill & Melinda Gates fdn.              |
|              |                     |                     |  |   |   |                    | 70%       | 48  | 3  | 8  | 47   | 106   |                               |  |   |   |
|              |                     |                     |  |   |   |                    | 80%       | 58  | 3  | 9  | 36   | 106   |                               |  |   |   |
| Pal (24)     | 2018                | Cross-sectional DTA | U.S.   | Healthy volunteers blood donors in two clinical centers (New York and Miami)        | Healthy adults, ≥ 18 years old, with an African American origin.                              | Fresh venous blood | 30%       | 84  | 0  | 10 | 320  | 414   | STANDARD™ G6PD (SD Biosensor) | Spectrophotometry for G6PD using the kit Pointe Scientific (for Thailand, the Trinity Biotech assay was used). | None  | UK's DFID, Bill & Melinda Gates fdn., MORU-Wellcome Trust               |
|              |                     |                     |  |   |   |                    | 70%       | 105   | 5  | 9  | 295  | 414   |                               |  |   |   |
|              |                     |                     |  |   |   |                    | 80%       | 115   | 6  | 40 | 253  | 414   |                               |  |   |   |
|              | Cross-sectional DTA | Thailand            | Participants attended two clinical centers located north and south of Mae Sot that serve a migrant population of Burman and Karen ethnic groups. | Adults with known G6PD status joined the study to achieve a convenience sample.     | Frozen venous blood   | 30%                | 54        | 0   | 5  | 91 | 150  |       |                               |  |   |   |
|              |                     |                     |  |   |   | 70%                | 96        | 5   | 9  | 40 | 150  |       |                               |  |   |   |
|              |                     |                     |  |   |   | 80%                | 103       | 4   | 11 | 32 | 150  |       |                               |  |   |   |

Abbreviations: TP: True Positives; FN: False Negatives; FP: False Positives; TN: True Negatives; G6PD: Glucose-6-Phosphate Dehydrogenase; DTA: Diagnostic Test Accuracy; U.S.: United States of America; U.K.: United Kingdom; FCDO: Foreign, Commonwealth & Development Office; fdn.: foundation; DFAT Department of Foreign Affairs and Trade, DFID: Department for International Development; MORU: Mahidol Oxford Tropical Medicine Research Unit

**Table 2.** Pooled DTA values for each threshold defined by Standard™ G6PD (SD Biosensor) test.

| G6PD activity threshold | Sensitivity (95%CI) & CoE                             | Specificity (95%CI) & CoE                            | +LR (95%CI)         | -LR (95%CI)            |
|-------------------------|---|--|---------------------|------------------------|
| 30%                     | 99.1% (96.9%-99.7%)<br>(4 studies, 3122 participants) | 97.4% (95.2-98.4%)<br>(4 studies, 3122 participants) | 35.3<br>(20.7-60.5) | 0.009<br>(0.003-0.031) |
|                         | High ⊕⊕⊕⊕   | High ⊕⊕⊕⊕  |                     |                        |
| 70%                     | 95.7% (92.9-97.4%)<br>(4 studies, 2371 participants)  | 92.8% (85.8-96.5%)<br>(4 studies, 2371 participants) | 13.2<br>(6.8-26.5)  | 0.046<br>(0.030-0.073) |
|                         | High ⊕⊕⊕⊕   | High ⊕⊕⊕⊕  |                     |                        |
| 80%                     | 90.5% (78.4-96.2%)<br>(4 studies, 2371 participants)  | 89.0% (76.9-95.1%)<br>(4 studies, 2371 participants) | 8.2<br>(4.1-16.0)   | 0.106<br>(0.049-0.227) |
|                         | Low ⊕⊕○○  | Moderate ⊕⊕⊕○  |                     |                        |

medRxiv preprint doi: <https://doi.org/10.1101/2024.02.10.24302326>; this version posted February 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

*Abbreviations: CI: confidence interval, LR: likelihood ratio, +: positive, -: negative, CoE: Certainty of the Evidence*